These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24151520)

  • 1. The role of IL-33 in rheumatic diseases.
    Duan L; Chen J; Gong F; Shi G
    Clin Dev Immunol; 2013; 2013():924363. PubMed ID: 24151520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-1 family of cytokines and receptors in rheumatic diseases.
    Dinarello CA
    Nat Rev Rheumatol; 2019 Oct; 15(10):612-632. PubMed ID: 31515542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-35: a new immunomodulator in autoimmune rheumatic diseases.
    Sakkas LI; Mavropoulos A; Perricone C; Bogdanos DP
    Immunol Res; 2018 Jun; 66(3):305-312. PubMed ID: 29749583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for interleukin-33 in T(H)2-polarized intestinal inflammation?
    Seidelin JB; Rogler G; Nielsen OH
    Mucosal Immunol; 2011 Sep; 4(5):496-502. PubMed ID: 21613987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological role of Interleukin 33 and its importance in pathophysiology of cardiovascular system].
    Czyzewska-Buczyńska A; Zuk N; Romanowska-Micherda K; Witkiewicz W
    Postepy Hig Med Dosw (Online); 2014; 68():834-41. PubMed ID: 24988604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.
    Bulek K; Swaidani S; Qin J; Lu Y; Gulen MF; Herjan T; Min B; Kastelein RA; Aronica M; Kosz-Vnenchak M; Li X
    J Immunol; 2009 Mar; 182(5):2601-9. PubMed ID: 19234154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor.
    Suzukawa M; Iikura M; Koketsu R; Nagase H; Tamura C; Komiya A; Nakae S; Matsushima K; Ohta K; Yamamoto K; Yamaguchi M
    J Immunol; 2008 Nov; 181(9):5981-9. PubMed ID: 18941187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis.
    Davies R; Choy E
    Semin Immunol; 2014 Feb; 26(1):97-104. PubMed ID: 24389239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.
    Miller AM; Liew FY
    Pharmacol Ther; 2011 Aug; 131(2):179-86. PubMed ID: 21356240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases.
    Sherlock JP; Taylor PC; Buckley CD
    Curr Opin Rheumatol; 2015 Jan; 27(1):71-5. PubMed ID: 25415528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.
    Pastorelli L; Garg RR; Hoang SB; Spina L; Mattioli B; Scarpa M; Fiocchi C; Vecchi M; Pizarro TT
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):8017-22. PubMed ID: 20385815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-33: a potential therapeutic target in autoimmune diseases.
    Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
    J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives.
    Ramezani F; Babaie F; Aslani S; Hemmatzadeh M; Mohammadi FS; Gowhari-Shabgah A; Jadidi-Niaragh F; Ezzatifar F; Mohammadi H
    Immunol Invest; 2022 May; 51(4):1060-1086. PubMed ID: 33522348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-32 as a biomarker in rheumatic diseases: A narrative review.
    Kwon OC; Park MC; Kim YG
    Front Immunol; 2023; 14():1140373. PubMed ID: 36875066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases.
    Vocca L; Di Sano C; Uasuf CG; Sala A; Riccobono L; Gangemi S; Albano GD; Bonanno A; Gagliardo R; Profita M
    Immunobiology; 2015 Aug; 220(8):954-63. PubMed ID: 25747940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-33 Receptor (ST2) Signalling is Important for Regulation of Th2-Mediated Airway Inflammation in a Murine Model of Acute Respiratory Syncytial Virus Infection.
    Zeng S; Wu J; Liu J; Qi F; Liu B
    Scand J Immunol; 2015 Jun; 81(6):494-501. PubMed ID: 25721734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice.
    Sakai N; Van Sweringen HL; Quillin RC; Schuster R; Blanchard J; Burns JM; Tevar AD; Edwards MJ; Lentsch AB
    Hepatology; 2012 Oct; 56(4):1468-78. PubMed ID: 22782692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines and pregnancy in rheumatic disease.
    Østensen M; Förger F; Villiger PM
    Ann N Y Acad Sci; 2006 Jun; 1069():353-63. PubMed ID: 16855162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.
    Schmitz J; Owyang A; Oldham E; Song Y; Murphy E; McClanahan TK; Zurawski G; Moshrefi M; Qin J; Li X; Gorman DM; Bazan JF; Kastelein RA
    Immunity; 2005 Nov; 23(5):479-90. PubMed ID: 16286016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IL-33/ST2 pathway: therapeutic target and novel biomarker.
    Kakkar R; Lee RT
    Nat Rev Drug Discov; 2008 Oct; 7(10):827-40. PubMed ID: 18827826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.